Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18180118,C(max),"Following s.c. administration at doses rate of 1, 3 and 10 microg/kg, average C(max) ranged from 2.26+/-0.15 to 22.72+/-1.54 ng/ml, and AUC(0-infinity) ranged from 3.43+/-0.05 to 47.1+/-0.10 ng h/ml.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),[ng] / [ml],2.26,353,DB01276,Exenatide
,18180118,C(max),"Following s.c. administration at doses rate of 1, 3 and 10 microg/kg, average C(max) ranged from 2.26+/-0.15 to 22.72+/-1.54 ng/ml, and AUC(0-infinity) ranged from 3.43+/-0.05 to 47.1+/-0.10 ng h/ml.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),[ng] / [ml],22.72,354,DB01276,Exenatide
,18180118,AUC(0-infinity),"Following s.c. administration at doses rate of 1, 3 and 10 microg/kg, average C(max) ranged from 2.26+/-0.15 to 22.72+/-1.54 ng/ml, and AUC(0-infinity) ranged from 3.43+/-0.05 to 47.1+/-0.10 ng h/ml.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),[h·ng] / [ml],3.43,355,DB01276,Exenatide
,18180118,AUC(0-infinity),"Following s.c. administration at doses rate of 1, 3 and 10 microg/kg, average C(max) ranged from 2.26+/-0.15 to 22.72+/-1.54 ng/ml, and AUC(0-infinity) ranged from 3.43+/-0.05 to 47.1+/-0.10 ng h/ml.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),[h·ng] / [ml],47.1,356,DB01276,Exenatide
,18180118,absolute bioavailability,"As compared to the i.v. administration at a single dose of 3 microg/kg, the absolute bioavailability after s.c. administration were estimated to be 67.3+/-5.3, 75.1+/-4.7 and 72.7+/-8.4% for 1, 3 and 10 microg/kg dose, respectively.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),%,67.3,357,DB01276,Exenatide
,18180118,absolute bioavailability,"As compared to the i.v. administration at a single dose of 3 microg/kg, the absolute bioavailability after s.c. administration were estimated to be 67.3+/-5.3, 75.1+/-4.7 and 72.7+/-8.4% for 1, 3 and 10 microg/kg dose, respectively.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),%,75.1,358,DB01276,Exenatide
,18180118,absolute bioavailability,"As compared to the i.v. administration at a single dose of 3 microg/kg, the absolute bioavailability after s.c. administration were estimated to be 67.3+/-5.3, 75.1+/-4.7 and 72.7+/-8.4% for 1, 3 and 10 microg/kg dose, respectively.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),%,72.7,359,DB01276,Exenatide
,18180118,accumulation ratio,"After daily s.c. administration at 10 microg/kg for 7 consecutive days, the accumulation ratio was approximately to 1.0, indicating no accumulation upon multiple doses in the monkeys.",Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180118/),,1.0,360,DB01276,Exenatide
,28870261,drug loading efficiency,EXT-SBA-15 showed a higher drug loading efficiency (15.2 ± 2.0%) and sustained-release features in vitro.,Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870261/),%,15.2,5231,DB01276,Exenatide
,28870261,half-life t 1/2(β),"In addition, pharmacokinetic studies revealed that the EXT-SBA-15 treatment group extended the half-life t 1/2(β) to 14.53 ± 0.70 h compared with that of the EXT solution (EXT-Sol) treatment group (0.60 ± 0.08 h) in vivo.",Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870261/),h,14.53,5232,DB01276,Exenatide
,28870261,half-life t 1/2(β),"In addition, pharmacokinetic studies revealed that the EXT-SBA-15 treatment group extended the half-life t 1/2(β) to 14.53 ± 0.70 h compared with that of the EXT solution (EXT-Sol) treatment group (0.60 ± 0.08 h) in vivo.",Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870261/),h,0.60,5233,DB01276,Exenatide
,30309736,h,The hypoglycemic time after single administration of PE on db/db mice was prolonged from 8.4 h to 54.9 h.,"C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30309736/),,54,8986,DB01276,Exenatide
,30309736,half-life,"When the in vivo single- and multiple-dose pharmacokinetics of PE were examined in Sprague-Dawley rats, the half-life was prolonged to 31.7 h, and no accumulation effect was observed.","C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30309736/),h,31.7,8987,DB01276,Exenatide
,31479925,elimination half-lives,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),min,∼40,14392,DB01276,Exenatide
,31479925,bioavailability,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),%,93,14393,DB01276,Exenatide
,31479925,bioavailability,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),%,52,14394,DB01276,Exenatide
,31479925,half-life,"Finally, subcutaneous injection of a microsphere-[Gln28]exenatide conjugate containing an appropriate self-cleaving linker in the cat provides plasma [Gln28]exenatide with a half-life of about 40 d vs 40 min with the injected free peptide.",A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),d,40,14395,DB01276,Exenatide
,31479925,half-life,"Finally, subcutaneous injection of a microsphere-[Gln28]exenatide conjugate containing an appropriate self-cleaving linker in the cat provides plasma [Gln28]exenatide with a half-life of about 40 d vs 40 min with the injected free peptide.",A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),min,40,14396,DB01276,Exenatide
,27169293,half-life (t½,"However, native GLP-1 is not suitable for treatment of diabetes due to its short half-life (t½, 2-5 min).",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),min,2-5,15581,DB01276,Exenatide
up to,27169293,t½,"Exendin-4 is a polypeptide isolated from lizard saliva, which can bind to GLP-1 receptor, produce physiological effects similar to GLP-1, t½ up to 2.5 h, therefore, we developed a long-lasting GLP-1 receptor agonists and GLP-1-exendin-4 fusion IgG4 Fc [GLP-1-exendin-4/ IgG4(Fc)].",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),h,2.5,15582,DB01276,Exenatide
,27169293,biological half-life,"Natural biological half-life of exendin-4 was (1.39 ± 0.28) h, GLP-1 in vivo t½ 4 min, indicating that fusion protein has long-lasting effects on the modulation of glucose homeostasis.",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),h,1.39,15583,DB01276,Exenatide
,27169293,t½,"Natural biological half-life of exendin-4 was (1.39 ± 0.28) h, GLP-1 in vivo t½ 4 min, indicating that fusion protein has long-lasting effects on the modulation of glucose homeostasis.",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),min,4,15584,DB01276,Exenatide
,22659626,k(a),"Exenatide exhibited rapid absorption with k(a)=4.45 h(-1), and the two-compartment model well described its pharmacokinetic profile.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),1/[h],4.45,16437,DB01276,Exenatide
,22659626,S(m1),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.822,16438,DB01276,Exenatide
,22659626,SC(50),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),[μg] / [l],4.02,16439,DB01276,Exenatide
,22659626,S(m2),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0513,16440,DB01276,Exenatide
,22659626,I(m),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0381,16441,DB01276,Exenatide
,33876430,Css,The Simcyp® simulated Css of the ER was 117 ng/L.,Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33876430/),[ng] / [l],117,31503,DB01276,Exenatide
,16100297,"Cmax,ss","Exenatide coadministration did not change the overall 24-hour steady-state digoxin exposure (AUCtau,ss) and Cmin,ss but caused a 17% decrease in mean plasma digoxin Cmax,ss (1.40 to 1.16 ng/mL) and an increase in digoxin tmax,ss (median increase, 2.5 hours).",Effect of exenatide on the steady-state pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100297/),[ng] / [ml],1.40 to 1.16,38102,DB01276,Exenatide
,21645806,AUC ratio,"Insulin area under the curve (AUC) during ExIGC was significantly higher than insulin AUC during IGC (AUC ratio, 2.0 ± 0.4; P = 0.03).",The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645806/),,2.0,38491,DB01276,Exenatide
,26930186,"t1/2,β","Pharmacokinetic analysis showed a t1/2,β of released exenatide of about 7 days which represents over a 300-fold half-life extension in the rat and exceeds the half-life of any currently approved long-acting GLP-1 agonist.",Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26930186/),d,7,42741,DB01276,Exenatide
,27650681,linear clearance,"For a subject with normal renal function, the linear clearance was estimated to be 5.06 l hr-1 .",Population pharmacokinetics of exenatide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650681/),[l] / [h],5.06,51133,DB01276,Exenatide
,27650681,Michaelis-Menten constant (Km ),The nonlinear elimination was quantified with a Michaelis-Menten constant (Km ) of 567 pg ml-1 and a maximum rate of metabolism (Vmax ) of 1.6 μg h-1 .,Population pharmacokinetics of exenatide. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650681/),[pg] / [ml],567,51134,DB01276,Exenatide
,27650681,maximum rate of metabolism (Vmax ),The nonlinear elimination was quantified with a Michaelis-Menten constant (Km ) of 567 pg ml-1 and a maximum rate of metabolism (Vmax ) of 1.6 μg h-1 .,Population pharmacokinetics of exenatide. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650681/),[μg] / [h],1.6,51135,DB01276,Exenatide
,30572033,loading efficiency,The Ex-4 loading efficiency was 77% and the loading content in the nanoparticles was 1 wt-%.,Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30572033/),%,77,54085,DB01276,Exenatide
,30572033,loading content,The Ex-4 loading efficiency was 77% and the loading content in the nanoparticles was 1 wt-%.,Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30572033/),,1,54086,DB01276,Exenatide
,30572033,relative oral bioavailability,"In rat models, a single oral dose (200 μg/kg) of EL-CSG showed a relative oral bioavailability of 19.5%, compared with subcutaneous administration (20 μg/kg), and sustained pharmacokinetics for up to 72 h.",Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30572033/),%,19.5,54087,DB01276,Exenatide
,28932995,peak-reaching time (t max),rE-4 was absorbed quickly with a median peak-reaching time (t max) of 0.8-1.5 h and eliminated rapidly with a median terminal half-life (t 1/2z) of 1.6-1.9 h.,Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932995/),h,0.8-1.5,54116,DB01276,Exenatide
,28932995,terminal half-life (t 1/2z),rE-4 was absorbed quickly with a median peak-reaching time (t max) of 0.8-1.5 h and eliminated rapidly with a median terminal half-life (t 1/2z) of 1.6-1.9 h.,Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932995/),h,1.6-1.9,54117,DB01276,Exenatide
,18291606,k(e),"In rats, elimination kinetics were similar for all routes of administration (median k(e) 0.017 min(-1)).",Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291606/),1/[min],0.017,58286,DB01276,Exenatide
,18291606,bioavailability,"For gastrointestinal administration, sublingual administration invoked the highest bioavailability (0.37%); in db/db mice, potentially therapeutic concentrations were obtainable.",Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291606/),%,0.37,58287,DB01276,Exenatide
,18291606,bioavailability,"In contrast, intraduodenal bioavailability was low (0.0053%).",Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291606/),%,0.0053,58288,DB01276,Exenatide
up,18291606,bioavailability,"In regard to respiratory surfaces, bioavailability of intratracheal exenatide was up to 13.6%, and for nasal administration, 1.68%.",Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291606/),%,13.6,58289,DB01276,Exenatide
,18291606,bioavailability,"In regard to respiratory surfaces, bioavailability of intratracheal exenatide was up to 13.6%, and for nasal administration, 1.68%.",Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291606/),%,1.68,58290,DB01276,Exenatide
,30627822,en,"Exe-PLGA-MPs with dimpled shapes and uniform particle sizes achieved a high encapsulation efficiency (EE%, 91.50 ± 2.65%) and sustained drug release for 2 months in vitro with reduced initial burst (20.42 ± 1.64%).","Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627822/),%,91.50,63183,DB01276,Exenatide
,30627822,EE%,"Exe-PLGA-MPs with dimpled shapes and uniform particle sizes achieved a high encapsulation efficiency (EE%, 91.50 ± 2.65%) and sustained drug release for 2 months in vitro with reduced initial burst (20.42 ± 1.64%).","Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627822/),%,91.50,63184,DB01276,Exenatide
more,28619366,half-life,"In in vivo pharmacokinetic study, the half-life of BPI-3016 was more than 95h after single dosing in diabetic cynomolgus monkeys.","BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28619366/),h,95,73759,DB01276,Exenatide
,24465870,bioavailability,"The bioavailability of the exenatide-loaded microspheres, relative to subcutaneous injection of exenatide, reached 10.2%.",Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465870/),%,10.2,74023,DB01276,Exenatide
,33455296,log Pbutanol/water,Hydrophobic ion pairing increased the log Pbutanol/water of exenatide from -1.9 to 2.0 for exenatide-SOS and to 1.2 for exenatide-DOC.,The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455296/),,1.9,74897,DB01276,Exenatide
,33455296,log Pbutanol/water,Hydrophobic ion pairing increased the log Pbutanol/water of exenatide from -1.9 to 2.0 for exenatide-SOS and to 1.2 for exenatide-DOC.,The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455296/),,2.0,74898,DB01276,Exenatide
,33455296,log Pbutanol/water,Hydrophobic ion pairing increased the log Pbutanol/water of exenatide from -1.9 to 2.0 for exenatide-SOS and to 1.2 for exenatide-DOC.,The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455296/),,1.2,74899,DB01276,Exenatide
,33455296,relative oral bioavailability,"The orally administered exenatide-SOS-loaded SEDDS and exenatide-DOC-loaded SEDDS resulted in relative oral bioavailability vs. subcutaneous injection (SC) of 19.6 and 15.2%, respectively.",The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455296/),%,19.6,74900,DB01276,Exenatide
,33455296,relative oral bioavailability,"The orally administered exenatide-SOS-loaded SEDDS and exenatide-DOC-loaded SEDDS resulted in relative oral bioavailability vs. subcutaneous injection (SC) of 19.6 and 15.2%, respectively.",The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455296/),%,15.2,74901,DB01276,Exenatide
,23318502,half-life,The half-life of GLP-1 was significantly increased when the COOH-terminal extension of Ex-4 was added (GLP-1 4.8±3.3min; GLP-Ex 19.5±3.3min).,"The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318502/),min,4.8,76132,DB01276,Exenatide
,23318502,half-life,The half-life of GLP-1 was significantly increased when the COOH-terminal extension of Ex-4 was added (GLP-1 4.8±3.3min; GLP-Ex 19.5±3.3min).,"The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318502/),min,19.5,76133,DB01276,Exenatide
,23318502,Ex-4,"In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1min; Ex(1-30) 28.4±1.7min).","The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318502/),min,32.4,76134,DB01276,Exenatide
,23318502,Ex(1-30),"In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1min; Ex(1-30) 28.4±1.7min).","The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318502/),min,28.4,76135,DB01276,Exenatide
,22344551,Cmax,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[pg] / [ml],77.7,89282,DB01276,Exenatide
,22344551,Cmax,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[pg] / [ml],136.1,89283,DB01276,Exenatide
,22344551,AUC0-t,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],184.2,89284,DB01276,Exenatide
,22344551,AUC0-t,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],309.7,89285,DB01276,Exenatide
,22344551,AUC0-∞,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],225.8,89286,DB01276,Exenatide
,22344551,AUC0-∞,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],365.4,89287,DB01276,Exenatide
,22344551,tmax,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.00,89288,DB01276,Exenatide
,22344551,t1/2,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.4,89289,DB01276,Exenatide
,22344551,t1/2,"Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5-10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0-t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0-∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75-1.50) and 1.00 (0.75-1.50) h; t1/2 (mean [range])=1.4 (0.7-3.2) and 1.8 (1.0-2.5) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.8,89290,DB01276,Exenatide
,22344551,Cmax,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[pg] / [ml],81.2,89291,DB01276,Exenatide
,22344551,Cmax,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[pg] / [ml],144.5,89292,DB01276,Exenatide
,22344551,AUC0-t,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],181.1,89293,DB01276,Exenatide
,22344551,AUC0-t,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],275.6,89294,DB01276,Exenatide
,22344551,AUC0-∞,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],217.2,89295,DB01276,Exenatide
,22344551,AUC0-∞,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),[h·pg] / [ml],313.3,89296,DB01276,Exenatide
,22344551,tmax,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.10,89297,DB01276,Exenatide
,22344551,tmax,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.00,89298,DB01276,Exenatide
,22344551,t1/2,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.6,89299,DB01276,Exenatide
,22344551,t1/2,"Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0-t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0-∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75-1.25) and 1.00 (1.00-1.25) h; t1/2=1.6 (0.8-2.2) and 1.4 (0.9-2.7) h, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),h,1.4,89300,DB01276,Exenatide
,22344551,percentage of maximal decline,"Mean percentage of maximal decline for serum glucose concentrations after single and multiple doses were 15.6% and 19.9% for 5 μg, respectively; as well as 26.3% and 28.7% for 10 μg, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),%,15.6,89301,DB01276,Exenatide
,22344551,percentage of maximal decline,"Mean percentage of maximal decline for serum glucose concentrations after single and multiple doses were 15.6% and 19.9% for 5 μg, respectively; as well as 26.3% and 28.7% for 10 μg, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),%,19.9,89302,DB01276,Exenatide
,22344551,percentage of maximal decline,"Mean percentage of maximal decline for serum glucose concentrations after single and multiple doses were 15.6% and 19.9% for 5 μg, respectively; as well as 26.3% and 28.7% for 10 μg, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),%,26.3,89303,DB01276,Exenatide
,22344551,percentage of maximal decline,"Mean percentage of maximal decline for serum glucose concentrations after single and multiple doses were 15.6% and 19.9% for 5 μg, respectively; as well as 26.3% and 28.7% for 10 μg, respectively.","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22344551/),%,28.7,89304,DB01276,Exenatide
,18793576,tmax,"Exenatide, 5 microg and 10 microg, was rapidly absorbed with a median tmax of 1 h after single and multiple doses.",Exenatide pharmacokinetics in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),h,1,91745,DB01276,Exenatide
,18793576,Cmax,"Exenatide Cmax and AUCtau,ss were (geometric mean (90% CI)) 145 (119 - 176) pg/ml and 370 (297 - 460) pg x h/ml, respectively, after multiple dosing with 5 microg.",Exenatide pharmacokinetics in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),[pg] / [ml],145,91746,DB01276,Exenatide
,18793576,"AUCtau,ss","Exenatide Cmax and AUCtau,ss were (geometric mean (90% CI)) 145 (119 - 176) pg/ml and 370 (297 - 460) pg x h/ml, respectively, after multiple dosing with 5 microg.",Exenatide pharmacokinetics in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),[h·pg] / [ml],370,91747,DB01276,Exenatide
,18793576,Cmax,"The Cmax and AUCtau,ss were 311 (271 - 357) pg/ml and 878 (785 - 983) pg x h/ml, respectively, for 10 microg.",Exenatide pharmacokinetics in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),[pg] / [ml],311,91748,DB01276,Exenatide
,18793576,"AUCtau,ss","The Cmax and AUCtau,ss were 311 (271 - 357) pg/ml and 878 (785 - 983) pg x h/ml, respectively, for 10 microg.",Exenatide pharmacokinetics in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),[h·pg] / [ml],878,91749,DB01276,Exenatide
,18793576,half-life (t1/2,"Mean half-life (t1/2, range 0.99 - 1.25 h), apparent volume of distribution (Vz/F, 19.2 - 22.3 l), and apparent clearance (CL/F, range 11.4 - 13.5 l/h) remained consistent between single and multiple doses and across the two dose levels.",Exenatide pharmacokinetics in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),h,0.99 - 1.25,91750,DB01276,Exenatide
,18793576,apparent volume of distribution (Vz/F,"Mean half-life (t1/2, range 0.99 - 1.25 h), apparent volume of distribution (Vz/F, 19.2 - 22.3 l), and apparent clearance (CL/F, range 11.4 - 13.5 l/h) remained consistent between single and multiple doses and across the two dose levels.",Exenatide pharmacokinetics in healthy Chinese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),l,19.2 - 22.3,91751,DB01276,Exenatide
,18793576,apparent clearance (CL/F,"Mean half-life (t1/2, range 0.99 - 1.25 h), apparent volume of distribution (Vz/F, 19.2 - 22.3 l), and apparent clearance (CL/F, range 11.4 - 13.5 l/h) remained consistent between single and multiple doses and across the two dose levels.",Exenatide pharmacokinetics in healthy Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793576/),[l] / [h],11.4 - 13.5,91752,DB01276,Exenatide
,19446153,AUC(0-infinity),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],339.5,92060,DB01276,Exenatide
,19446153,C(max),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],85.1,92061,DB01276,Exenatide
,19446153,AUC(0-infinity)),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],159.2,92062,DB01276,Exenatide
,19446153,C(max),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],56.3,92063,DB01276,Exenatide
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-3465.6,92064,DB01276,Exenatide
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-,92065,DB01276,Exenatide
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],4422.2,92066,DB01276,Exenatide
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],3457.4,92067,DB01276,Exenatide
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],125.5,92068,DB01276,Exenatide
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],-1403.8,92069,DB01276,Exenatide
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],1843.1,92070,DB01276,Exenatide
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB01276,Exenatide
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB01276,Exenatide
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB01276,Exenatide
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB01276,Exenatide
,19900495,elimination half-life,"Furthermore, the pharmacokinetic characteristics were dramatically enhanced, that is, absorption was delayed and elimination half-life was increased (1.6+/-0.4 and 9.7+/-1.4h by exendin-4 and LCA-M1, respectively).","Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19900495/),h,1.6,102049,DB01276,Exenatide
,19900495,elimination half-life,"Furthermore, the pharmacokinetic characteristics were dramatically enhanced, that is, absorption was delayed and elimination half-life was increased (1.6+/-0.4 and 9.7+/-1.4h by exendin-4 and LCA-M1, respectively).","Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19900495/),h,9.7,102050,DB01276,Exenatide
,17323791,time to maximum plasma concentration (tmax),"In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours.",Exenatide effects on statin pharmacokinetics and lipid response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323791/),h,4,102126,DB01276,Exenatide
,23770254,C(max),The plasma concentration of the single dose of the sustained-release microspheres attained C(max) of 108.19±14.92 ng/ml at t(max) of 1.33±0.58 h and the t(½) was 120.65±44.18 h.,Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23770254/),[ng] / [ml],108.19,109922,DB01276,Exenatide
,23770254,t(max),The plasma concentration of the single dose of the sustained-release microspheres attained C(max) of 108.19±14.92 ng/ml at t(max) of 1.33±0.58 h and the t(½) was 120.65±44.18 h.,Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23770254/),h,1.33,109923,DB01276,Exenatide
,23770254,t(½),The plasma concentration of the single dose of the sustained-release microspheres attained C(max) of 108.19±14.92 ng/ml at t(max) of 1.33±0.58 h and the t(½) was 120.65±44.18 h.,Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23770254/),h,120.65,109924,DB01276,Exenatide
,31368418,t1/2,Pharmacokinetic studies revealed that the t1/2 of LA-EX (5.95 h) was 2.3-fold longer than that of EX.,Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368418/),h,5.95,111991,DB01276,Exenatide
,32006325,peak time,"The pharmacokinetics of polyethylene glycolated exenatide was studied in 36 subjects, which showed slow absorption, a mean peak time of 20-40 h, and a mean elimination half-life of 51-64 h.","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32006325/),h,20-40,132348,DB01276,Exenatide
,32006325,elimination half-life,"The pharmacokinetics of polyethylene glycolated exenatide was studied in 36 subjects, which showed slow absorption, a mean peak time of 20-40 h, and a mean elimination half-life of 51-64 h.","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32006325/),h,51-64,132349,DB01276,Exenatide
,23058052,half-life,In SD rats its half-life was prolonged to 27.12 ± 5.75 h which was 17.61-fold longer than that of the natural exendin-4 for which the half-life was only 1.54 ± 0.47 h.,A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058052/),h,27.12,139183,DB01276,Exenatide
,23058052,half-life,In SD rats its half-life was prolonged to 27.12 ± 5.75 h which was 17.61-fold longer than that of the natural exendin-4 for which the half-life was only 1.54 ± 0.47 h.,A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058052/),h,1.54,139184,DB01276,Exenatide
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,55.67,146410,DB01276,Exenatide
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,56.99,146411,DB01276,Exenatide
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,54.81,146412,DB01276,Exenatide
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],4.22,146413,DB01276,Exenatide
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],6.03,146414,DB01276,Exenatide
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],10.50,146415,DB01276,Exenatide
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],708.59,146416,DB01276,Exenatide
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],1012.63,146417,DB01276,Exenatide
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],1763.81,146418,DB01276,Exenatide
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.15,146419,DB01276,Exenatide
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.17,146420,DB01276,Exenatide
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.14,146421,DB01276,Exenatide
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],241.25,146422,DB01276,Exenatide
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],341.53,146423,DB01276,Exenatide
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],450.06,146424,DB01276,Exenatide
,24086950,elimination half-life,"Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours.",Lixisenatide for the treatment of type 2 diabetes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086950/),h,2-3,154900,DB01276,Exenatide
,33197556,droplet size,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,24.28,160257,DB01276,Exenatide
,33197556,polydispersity index,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.17,160258,DB01276,Exenatide
,33197556,zeta potential,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.17,160259,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,-,160260,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,1.28,160261,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),m,79.60,160262,DB01276,Exenatide
,33197556,droplet size,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,20.25,160263,DB01276,Exenatide
,33197556,polydispersity index,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.11,160264,DB01276,Exenatide
,33197556,zeta potential,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.11,160265,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,-,160266,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,1.85,160267,DB01276,Exenatide
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),m,100.02,160268,DB01276,Exenatide
,29648441,bioavailability,"The mean bioavailability was 20% relative to subcutaneous administration, even though it fell short of 1% when exendin-4 alone was administered nasally.",Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648441/),%,20,166133,DB01276,Exenatide
,29648441,bioavailability,"The mean bioavailability was 20% relative to subcutaneous administration, even though it fell short of 1% when exendin-4 alone was administered nasally.",Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648441/),%,1,166134,DB01276,Exenatide
more,30389472,gelation time,The gelation time of the EXT/CS/GP/MgCl2 hydrogel (more than 110 min) at 37 °C was much longer than that of the EXT/CS/GP/CaCl2 hydrogel (8.0-20.4 min).,Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30389472/),min,110,168598,DB01276,Exenatide
,30389472,gelation time,The gelation time of the EXT/CS/GP/MgCl2 hydrogel (more than 110 min) at 37 °C was much longer than that of the EXT/CS/GP/CaCl2 hydrogel (8.0-20.4 min).,Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30389472/),min,8.0-20.4,168599,DB01276,Exenatide
,15199095,Apparent,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0386,179397,DB01276,Exenatide
,15199095,elimination rate constants,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0386,179398,DB01276,Exenatide
,15199095,elimination rate constants,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0460,179399,DB01276,Exenatide
,17994612,plasma half-life (t(1/2),"But to gain a continued effect, the peptide has to be injected twice a day owing to its short plasma half-life (t(1/2) = 2.4 h).",Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17994612/),h,2.4,182751,DB01276,Exenatide
,25723538,half-life,"Exendin-4 had a half-life of 7.8 and 100.9 min in the kidney and liver homogenate, respectively.",In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25723538/),min,7.8,185818,DB01276,Exenatide
,25723538,half-life,"Exendin-4 had a half-life of 7.8 and 100.9 min in the kidney and liver homogenate, respectively.",In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25723538/),min,100.9,185819,DB01276,Exenatide
,17292977,ED(50),The ED(50) values of AC3174 for glucose lowering (60 minute post-dose) were 1.2 microg/kg in db/db mice and 1.3 microg/kg in C57BL/6 mice.,"Biological activity of AC3174, a peptide analog of exendin-4. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),[μg] / [kg],1.2,186269,DB01276,Exenatide
,17292977,ED(50),The ED(50) values of AC3174 for glucose lowering (60 minute post-dose) were 1.2 microg/kg in db/db mice and 1.3 microg/kg in C57BL/6 mice.,"Biological activity of AC3174, a peptide analog of exendin-4. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),[μg] / [kg],1.3,186270,DB01276,Exenatide
,17292977,half-life,"In rats, the in vivo half-life of AC3174 was 42-43 min following SC administration.","Biological activity of AC3174, a peptide analog of exendin-4. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),min,42-43,186271,DB01276,Exenatide
,29619854,relative bioavailability,The relative bioavailability of Tf-exenatide-Zn2+-NPs versus subcutaneous injection of exenatide was 6.45%.,Tf ligand-receptor-mediated exenatide-Zn2+ complex oral-delivery system for penetration enhancement of exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619854/),%,6.45,187131,DB01276,Exenatide
,19706990,steady-state plasma concentrations,"For the evaluable pharmacokinetic population, geometric mean (90% confidence interval) steady-state plasma concentrations (pg/mL) were 81.2 (68.3-96.4) and 344.5 (256.5-462.7) with exenatide QW 0.8 mg (n=8) and exenatide QW 2.0 mg (n=5), respectively.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19706990/),[pg] / [ml],81.2,191866,DB01276,Exenatide
,19706990,steady-state plasma concentrations,"For the evaluable pharmacokinetic population, geometric mean (90% confidence interval) steady-state plasma concentrations (pg/mL) were 81.2 (68.3-96.4) and 344.5 (256.5-462.7) with exenatide QW 0.8 mg (n=8) and exenatide QW 2.0 mg (n=5), respectively.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19706990/),[pg] / [ml],344.5,191867,DB01276,Exenatide
,24144329,terminal half-life,Compound 10's terminal half-life of ~27 h should translate favorably to weekly dosing in humans.,Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144329/),h,27,200526,DB01276,Exenatide
,17425627,half-life,"Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),h,1.5,201228,DB01276,Exenatide
,17425627,half-life,"Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),h,2.1,201229,DB01276,Exenatide
,17425627,half-life,"Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),h,3.2,201230,DB01276,Exenatide
,17425627,half-life,"Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),h,6.0,201231,DB01276,Exenatide
,17425627,CLp/F,"After combining data from multiple studies, least squares geometric means for CLp/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h(-1), respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),[l] / [h],8.14,201232,DB01276,Exenatide
,17425627,CLp/F,"After combining data from multiple studies, least squares geometric means for CLp/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h(-1), respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),[l] / [h],5.19,201233,DB01276,Exenatide
,17425627,CLp/F,"After combining data from multiple studies, least squares geometric means for CLp/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h(-1), respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),[l] / [h],7.11,201234,DB01276,Exenatide
,17425627,CLp/F,"After combining data from multiple studies, least squares geometric means for CLp/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h(-1), respectively.",Effect of renal impairment on the pharmacokinetics of exenatide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425627/),[l] / [h],1.3,201235,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,60,205664,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,111,205665,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,169,205666,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,34,205667,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,87,205668,DB01276,Exenatide
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,114,205669,DB01276,Exenatide
,19047364,t(max),Exenatide was well absorbed with a median t(max) of 1.5 hours and mean t((1/2)) of 1.6 hours; exposure increased with dose.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19047364/),h,1.5,205985,DB01276,Exenatide
,19047364,t((1/2)),Exenatide was well absorbed with a median t(max) of 1.5 hours and mean t((1/2)) of 1.6 hours; exposure increased with dose.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19047364/),h,1.6,205986,DB01276,Exenatide
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [min],3.62,216826,DB01276,Exenatide
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [kg·min],2.39,216827,DB01276,Exenatide
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [kg·min],1.48,216828,DB01276,Exenatide
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),nM,0.74,216829,DB01276,Exenatide
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),pM,0.12,216830,DB01276,Exenatide
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),nM,1.38,216831,DB01276,Exenatide
,33839225,availability,The in vivo pharmacokinetic study showed a preferred hypoglycemic effect and an increased pharmacological availability (13.7 ± 4.1%) after oral administration of the EXE-PLGA NPs @YCWPs.,Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33839225/),%,13.7,221671,DB01276,Exenatide
,28513427,apparent clearance (CL/F),"The outcome parameters were as follows: apparent clearance (CL/F) 6.67 L/h, apparent distribution volume of central compartment (V<sub>c</sub>/F) 19.4 L, absorption rate constant (K<sub>a</sub>) 1.39 h<sup>-1</sup>, apparent distribution volume of peripheral compartment (V<sub>p</sub>/F) 22.6 L, intercompartmental clearance (Q/F) 1.28 L/h.","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513427/),[l] / [h],6.67,239611,DB01276,Exenatide
,28513427,apparent distribution volume of central compartment (V<sub>c</sub>/F),"The outcome parameters were as follows: apparent clearance (CL/F) 6.67 L/h, apparent distribution volume of central compartment (V<sub>c</sub>/F) 19.4 L, absorption rate constant (K<sub>a</sub>) 1.39 h<sup>-1</sup>, apparent distribution volume of peripheral compartment (V<sub>p</sub>/F) 22.6 L, intercompartmental clearance (Q/F) 1.28 L/h.","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513427/),l,19.4,239612,DB01276,Exenatide
,28513427,absorption rate constant (K<sub>a</sub>),"The outcome parameters were as follows: apparent clearance (CL/F) 6.67 L/h, apparent distribution volume of central compartment (V<sub>c</sub>/F) 19.4 L, absorption rate constant (K<sub>a</sub>) 1.39 h<sup>-1</sup>, apparent distribution volume of peripheral compartment (V<sub>p</sub>/F) 22.6 L, intercompartmental clearance (Q/F) 1.28 L/h.","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513427/),1/[h<sup>·sup>],1.39,239613,DB01276,Exenatide
,28513427,apparent distribution volume of peripheral compartment (V<sub>p</sub>/F),"The outcome parameters were as follows: apparent clearance (CL/F) 6.67 L/h, apparent distribution volume of central compartment (V<sub>c</sub>/F) 19.4 L, absorption rate constant (K<sub>a</sub>) 1.39 h<sup>-1</sup>, apparent distribution volume of peripheral compartment (V<sub>p</sub>/F) 22.6 L, intercompartmental clearance (Q/F) 1.28 L/h.","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513427/),l,22.6,239614,DB01276,Exenatide
,28513427,intercompartmental clearance (Q/F),"The outcome parameters were as follows: apparent clearance (CL/F) 6.67 L/h, apparent distribution volume of central compartment (V<sub>c</sub>/F) 19.4 L, absorption rate constant (K<sub>a</sub>) 1.39 h<sup>-1</sup>, apparent distribution volume of peripheral compartment (V<sub>p</sub>/F) 22.6 L, intercompartmental clearance (Q/F) 1.28 L/h.","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513427/),[l] / [h],1.28,239615,DB01276,Exenatide
,23747732,C(max),"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),[pg] / [ml],344,242257,DB01276,Exenatide
,23747732,T(max),"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),h,6,242258,DB01276,Exenatide
,23747732,bioavailability,"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),%,6.4,242259,DB01276,Exenatide
,21156817,T(max),"After intravenous doses, exendin-4 rapidly disappeared from the circulation, whereas it exhibited rapid absorption (T(max) = 15-20 min) and incomplete bioavailability (F = 0.51) after the subcutaneous dose.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),min,15-20,246594,DB01276,Exenatide
,21156817,bioavailability (F,"After intravenous doses, exendin-4 rapidly disappeared from the circulation, whereas it exhibited rapid absorption (T(max) = 15-20 min) and incomplete bioavailability (F = 0.51) after the subcutaneous dose.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),,0.51,246595,DB01276,Exenatide
,21156817,capacity S(max),"Exendin-4 increased insulin release at 2 to 5 min with capacity S(max) = 6.91 and sensitivity SC₅₀ = 1.29 nM, followed by a rebound at 10 to 15 min and a slow return to the baseline.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),,6.91,246596,DB01276,Exenatide
,21156817,sensitivity SC₅₀,"Exendin-4 increased insulin release at 2 to 5 min with capacity S(max) = 6.91 and sensitivity SC₅₀ = 1.29 nM, followed by a rebound at 10 to 15 min and a slow return to the baseline.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),nM,1.29,246597,DB01276,Exenatide
,28457895,Kd,"A phage display screen of a library of aptides, yielded an HSA-specific aptide (APTHSA) that bound HSA with a Kd of 188nM.",An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),nM,188,262938,DB01276,Exenatide
,28457895,plasma half-life,A pharmacokinetic analysis of exenatide-APTHSA after subcutaneous administration revealed a 4-fold longer plasma half-life (1.3 vs. 0.35h) compared with exenatide.,An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),h,1.3,262939,DB01276,Exenatide
,28457895,plasma half-life,A pharmacokinetic analysis of exenatide-APTHSA after subcutaneous administration revealed a 4-fold longer plasma half-life (1.3 vs. 0.35h) compared with exenatide.,An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),h,0.35,262940,DB01276,Exenatide
,24503632,circulating half lives,"Both molecules displayed picomolar and nanomolar binding association with albumin across multiple species and circulating half lives of 16 and 11 hours, respectively, post a single IV dose in rats.",Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24503632/),h,16,263940,DB01276,Exenatide
,24503632,circulating half lives,"Both molecules displayed picomolar and nanomolar binding association with albumin across multiple species and circulating half lives of 16 and 11 hours, respectively, post a single IV dose in rats.",Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24503632/),h,11,263941,DB01276,Exenatide
